HighTower Advisors LLC Sells 180 Shares of Repligen Co. (NASDAQ:RGEN)

HighTower Advisors LLC reduced its stake in Repligen Co. (NASDAQ:RGEN) by 3.4% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 5,054 shares of the biotechnology company’s stock after selling 180 shares during the quarter. HighTower Advisors LLC’s holdings in Repligen were worth $727,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Resources Management Corp CT ADV bought a new stake in shares of Repligen in the third quarter valued at about $37,000. Quarry LP lifted its stake in Repligen by 796.7% in the 3rd quarter. Quarry LP now owns 269 shares of the biotechnology company’s stock valued at $40,000 after acquiring an additional 239 shares in the last quarter. UMB Bank n.a. boosted its position in Repligen by 49.1% during the 4th quarter. UMB Bank n.a. now owns 334 shares of the biotechnology company’s stock worth $48,000 after acquiring an additional 110 shares during the last quarter. Global Retirement Partners LLC grew its stake in shares of Repligen by 54.0% during the 4th quarter. Global Retirement Partners LLC now owns 368 shares of the biotechnology company’s stock worth $53,000 after acquiring an additional 129 shares in the last quarter. Finally, GAMMA Investing LLC raised its holdings in shares of Repligen by 15.2% in the fourth quarter. GAMMA Investing LLC now owns 684 shares of the biotechnology company’s stock valued at $98,000 after purchasing an additional 90 shares during the last quarter. 97.64% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research analysts recently commented on the stock. HC Wainwright restated a “buy” rating and set a $180.00 target price on shares of Repligen in a report on Friday, February 21st. Canaccord Genuity Group raised their price objective on Repligen from $165.00 to $170.00 and gave the company a “hold” rating in a report on Friday, February 21st. JPMorgan Chase & Co. upped their target price on Repligen from $190.00 to $200.00 and gave the stock an “overweight” rating in a report on Friday, February 21st. Canaccord Genuity Group assumed coverage on Repligen in a research note on Tuesday, December 17th. They issued a “hold” rating and a $165.00 price target for the company. Finally, Royal Bank of Canada upped their price objective on Repligen from $203.00 to $205.00 and gave the stock an “outperform” rating in a research note on Friday, February 21st. One investment analyst has rated the stock with a sell rating, six have given a hold rating and eight have issued a buy rating to the stock. According to MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $178.64.

Insider Buying and Selling

In related news, Director Margaret Pax purchased 250 shares of the firm’s stock in a transaction that occurred on Monday, March 17th. The shares were bought at an average cost of $150.69 per share, with a total value of $37,672.50. Following the acquisition, the director now owns 1,043 shares of the company’s stock, valued at $157,169.67. This trade represents a 31.53 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. 1.20% of the stock is owned by company insiders.

Repligen Trading Down 2.7 %

RGEN stock opened at $133.41 on Friday. Repligen Co. has a one year low of $113.50 and a one year high of $184.98. The stock has a market cap of $7.49 billion, a price-to-earnings ratio of -261.59, a price-to-earnings-growth ratio of 4.54 and a beta of 0.95. The company has a fifty day moving average price of $154.21 and a two-hundred day moving average price of $148.14. The company has a debt-to-equity ratio of 0.26, a current ratio of 10.44 and a quick ratio of 8.76.

Repligen (NASDAQ:RGEN) last announced its earnings results on Thursday, February 20th. The biotechnology company reported $0.44 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.41 by $0.03. The company had revenue of $167.55 million during the quarter, compared to analysts’ expectations of $167.58 million. Repligen had a negative net margin of 4.64% and a positive return on equity of 4.21%. Equities analysts anticipate that Repligen Co. will post 1.72 EPS for the current year.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.